Table 1.
This table is a summary of the subjects with an ASD diagnosis finishing the treatment regimen employed in the present study.
| Descriptive information | Trans-dermal glutathione group | Oral glutathione group |
|---|---|---|
| Sex/age | ||
| Male/female (ratio) | 12/1 (12:1) | 10/3 (3.3:1) |
| Mean age in years ±Std (range) | 5.8±1.5 (4–9) | 7.5±2.9 (3–13) |
| Mean birth year ±Std (range) | 2001±1.6 (1998–2003) | 1999±2.8 (1995–2003) |
| Race (n) | ||
| Caucasian | 69.2% (9) | 69.2% (9) |
| Hispanic | 7.7% (1) | 0% (0) |
| Black | 7.7% (1) | 15.4% (2) |
| Asian | 7.7% (1) | 7.7% (1) |
| Mixed | 7.7% (1) | 7.7% (1) |
| Autistic disorder characteristics | ||
| Mean CARS score ± Std (range) | 34.8±6.04 (30–50) | 41.3±5.1 (30–51) |
| Regressive (n)* | 61.5% (8) | 61.5% (8) |
| Non-regressive (n) | 38.5% (5) | 38.5% (5) |
| Autism (n) | 61.5% (8) | 77% (10) |
| Autism spectrum disorders (n)** | 38.5% (5) | 23% (3) |
| Previous treatments | ||
| Supplements (n) | 23.1% (3) | 23.1% (3) |
| Chelation (n) | 0% (0) | 0% (0) |
| Supplements + chelation (n) | 7.7% (1) | 23.1% (3) |
Std – standard deviation. All participants examined in the present study were living in the state of Texas.
*
Includes participants that had a regressive event in development at any time following birth;
**
Autism spectrum disorders include participants diagnosed with pervasive developmental disorder – not otherwise specified (PDD-NOS) and Asperger’s disorder.